TNFRSF10B and neoplasm: In contrast, most patients have microsatellite‐stable (MSS) CRC, and therefore, do not benefit from ICIs.[3] Consequently, the challenge lies in enhancing tumor immunogenicity, increasing immune infiltration, and enhancing the response to ICIs in these patients.[4] Targeting death receptors, such as DR5, can induce tumor cell death, leading to immunogenic cell death (ICD).[5] However, its effectiveness is often reduced by apoptosis resistance and lethal inflammatory damage caused by systemic administration.